CEO’s trust sells 7,500 IRADIMED (IRMD) shares under Rule 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
IRADIMED CORP director and CEO Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, reported open‑market sales of 7,500 shares of Common Stock over May 18–19, 2026. Reported sale prices ranged from about $85.95 to $88.65 per share.
The filing notes these sales were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted by the reporting person on November 5, 2025, indicating the timing was set in advance. The trust continues to hold a substantial indirect stake in IRADIMED after these transactions, while Susi disclaims beneficial ownership beyond his pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Pre‑planned, modest insider sales via trust; overall stake remains large.
The transactions show the Phillip Susi 2008 Dynasty Trust, associated with CEO Roger E. Susi, selling 7,500 IRADIMED CORP common shares in open‑market trades at prices in the mid‑$80s. All reported movements are non‑derivative stock sales; there are no option exercises or conversions.
A key detail is that footnotes state the sales were made under a Rule 10b5‑1 trading plan adopted on November 5, 2025. Such plans schedule trades in advance, so the timing carries limited informational value about management’s current view of the stock. The Form 4 also reports ongoing indirect holdings in multiple trusts, suggesting these sales are small relative to Susi’s overall economic exposure, though exact aggregate holdings are not fully detailed here.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares ($657,265)
Net Sell
8 txns
Insider
Susi Roger E.
Role
CEO, President, Chairman
Sold
7,500 shs ($657K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 653 | $87.13 | $57K |
| Sale | Common Stock | 1,841 | $88.14 | $162K |
| Sale | Common Stock | 6 | $88.65 | $531.90 |
| Sale | Common Stock | 298 | $85.95 | $26K |
| Sale | Common Stock | 3,451 | $87.35 | $301K |
| Sale | Common Stock | 1,251 | $88.34 | $111K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,174,347 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $85.67 to $86.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $86.89 to $87.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $87.90 to $88.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $86.60 to $87.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $87.62 to $88.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares sold: 7,500 shares
Highest reported sale price: $88.65 per share
Lowest reported sale price: $85.95 per share
+1 more
4 metrics
Shares sold
7,500 shares
Total common stock sold across May 18–19, 2026
Highest reported sale price
$88.65 per share
Open-market sale price on May 19, 2026
Lowest reported sale price
$85.95 per share
Open-market sale price on May 18, 2026
Rule 10b5-1 plan adoption date
November 5, 2025
Plan governing reported insider sales
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, beneficial ownership, Section 16
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
beneficial ownership financial
"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16..."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider transactions did IRADIMED (IRMD) disclose for Roger E. Susi?
IRADIMED reported that a trust associated with CEO Roger E. Susi sold 7,500 shares of common stock in open‑market transactions. The sales occurred on May 18–19, 2026 at prices in the mid‑$80s per share, with all shares held indirectly through the Phillip Susi 2008 Dynasty Trust.
Were the IRADIMED (IRMD) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states that the sales reported were effected under a Rule 10b5‑1 trading plan adopted on November 5, 2025. These pre‑arranged plans automate trading according to preset instructions, which generally reduces the significance of the specific timing of each individual sale.